Exicure, Inc. (XCUR)
| Market Cap | 20.51M |
| Revenue (ttm) | 500,000 |
| Net Income (ttm) | -4.01M |
| Shares Out | 1.83M |
| EPS (ttm) | -2.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,842,607 |
| Open | 6.84 |
| Previous Close | 5.82 |
| Day's Range | 6.83 - 14.80 |
| 52-Week Range | 1.44 - 14.80 |
| Beta | 1.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2024 |
About XCUR
Exicure, Inc. does not have significant operations. previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. [Read more]
Financial Performance
Financial StatementsNews
Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results.
Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (“Panel”) gr...
Exicure, Inc. Announces 1-for-5 Reverse Stock Split
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Sp...
Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting.
Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting.
Exicure, Inc. Reports Second Quarter 2024 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2024 Financial Results.
Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics.
Exicure, Inc. Receives Positive Listing Determination from Nasdaq
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Receives Positive Listing Determination from Nasdaq.
Exicure, Inc. Reports First Quarter 2024 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic aci...
Exicure, Inc. Reports Full Year 2023 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Reports Full Year 2023 Financial Results.
Exicure, Inc. Received Nasdaq Notice of a Delisting Determination
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received notice of a delisting determination (the “Staff Delisting Determination”) from the List...
Exicure, Inc. Reports Third Quarter 2023 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against valid...
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on April 17, 2024 no...
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
CHICAGO--(BUSINESS WIRE)--Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company ...
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on November 22, 2023...
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. announces appointment of new CEO and CFO and changes to Board of Directors.
Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. reports second quarter 2023 financial results and provides corporate update.
Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. reports first quarter 2023 financial results and provides corporate update.
Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonuclei...
Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld
CHICAGO--(BUSINESS WIRE)--Exicure has invested in Cyworld Z Co. Ltd. through the purchase of $1 million aggregate principal amount of convertible bonds issued by Cyworld Z.
Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update
CHICAGO--(BUSINESS WIRE)--Exicure, Inc., reported financial results for the year ended December 31, 2022 and provided an update on its business strategy and corporate progress.
Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors
CHICAGO--(BUSINESS WIRE)--Exicure today announced the closing of the previously-announced private placement transaction with CBI USA, Inc. effective February 24, 2023.
Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR) an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated tar...
Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated ta...
Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives
CHICAGO--(BUSINESS WIRE)--Exicure announced plans to restructure the Company and align resources to continue exploring strategic alternatives that maximize stockholder value.